GlassScriptPhysician profile
Arlene A Harrington
NPI 1831126382
$4,399.09
in general payments reported to CMS, 2019-2025
28 companies · $914 in 2025
The $914 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $367 · 2021: $527 · 2022: $546 · 2023: $901 · 2024: $1,004 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,818.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $908.70 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $707.10 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $479.88 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $337.79 | 2020-2024 | Dyanavel Xr, Quillivant, Quillichew Er |
| Takeda Pharmaceuticals U.S.A., INC. | $329.56 | 2020-2025 | Elaprase |
| Collegium Pharmaceutical, INC. | $242.55 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $189.73 | 2022-2025 | Adzenys Xr-Odt |
| Ars Pharmaceuticals Operations, INC. | $180.18 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $165.71 | 2020-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Alk-Abello, INC | $162.96 | 2023-2025 | Odactra, Grastek, Ragwitek |
| Sanofi Pasteur INC. | $92.31 | 2020-2024 | |
| Seqirus USA INC | $89.04 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Cranial Technologies, INC | $78.23 | 2020-2023 | Doc Band |
| Kaleo, INC. | $75.71 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $62.70 | 2023-2025 | Flumist Quadrivalent |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $52.51 | 2019-2024 | |
| Phadia US INC. | $45.16 | 2020-2024 | Immunocap |
| Shire North American Group INC | $28.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.35 | 2019 | |
| Pfizer INC. | $21.32 | 2023 | |
| Biomerieux INC | $21.00 | 2025 | Biofire Spotfire Control Station |
| Vertical Pharmaceuticals, LLC | $19.85 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.01 | 2025 | Koselugo |
| Cumberland Pharmaceuticals, INC. | $17.58 | 2021 | |
| Dermira, INC. | $14.28 | 2020 | |
| Adlon Therapeutics L.P. | $12.24 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.07 | 2020 | |
| Genentech USA, INC. | $12.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arlene Harrington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.